To compare the effect of Tablet Apremilast with Tablet Tofacitinib in Psoriasis vulgaris treatment.

A comparitive study on the therapeutic efficacy of Tablet Apremilast and Tablet Tofacitinib in the treatment of chronic plaque type psoriasis - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/07/090447

Enrollment

Registered

2025-07-08

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L400- Psoriasis vulgaris

Interventions

Intervention1: Tablet Apremilast 30 mg OD: Group A will be given Tablet Apremilast 30mg OD daily Intervention2: Tablet Tofacitinib 5mg BD: Group B will be given Tablet Tofacitinib 5mg BD daily Control

Eligibility

Inclusion criteria

Inclusion criteria: Patients having plaque type psoriasis Patients who are willing to give consent to participate in the study Patients who could come for regular follow up

Exclusion criteria

Exclusion criteria: Pregnant and lactating mothers Patients with severe liver and kidney diseases Immunocompromised patients History of previous treatment History of known allergy to any drugs Concomitant use of CYP-450 inhibitors or inducers

Design outcomes

Primary

Measure	Time frame
80 percent power 95 percent confidence interval P value Timepoint: Psoriasis Area Severity Index Patients clinical response at baseline and at 4 weeks and at 8 weeks	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Balajiganesh

Thanjavur Medical College

drbalajikmu@gmail.com9865639594

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026